Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or quantitative synthesis
PubMed 41333115 · doi:10.1155/jobe/9919810
What was done
This narrative review summarized the therapeutic roles, clinical efficacy, safety profiles, adherence challenges, and limitations of FDA-approved and off-label GLP-1 receptor agonists (including liraglutide, semaglutide, and tirzepatide) for obesity. It also discussed pipeline agents (such as CagriSema, orforglipron, mazdutide, retatrutide, and survodutide) and the integration of digital health strategies.
What was found
The abstract reports no numerical values, effect sizes, or statistical findings. It qualitatively summarizes that GLP-1 receptor agonists deliver weight reduction and glycemic control with acceptable safety, while outlining anticipated expanded indications for chronic kidney disease, heart failure with preserved ejection fraction, and metabolic dysfunction-associated steatohepatitis.
Why it matters
It provides an overview of the shifting landscape in obesity pharmacology, particularly the progression toward dual and triple incretin receptor agonists and the impact of generic formulations on treatment accessibility.
Limits
As a narrative review, the paper does not use systematic search criteria, quality appraisal, or meta-analytic pooling. The abstract contains no primary data, sample sizes, or quantitative outcome metrics.
Cited by
- supports Liraglutide's patent has expired and generic versions of the drug are available.